January 18, 2022
Austin, TX – CReDO Science and EndoCanna Health are delighted to partner to provide a screening test for cannabinoid hyperemesis syndrome (CHS). CReDO Science CEO and the inventor of the screening technology, Ethan Russo, M.D. says, “CHS previously has been an enigmatic disorder that has been a tremendous burden of abdominal pain, nausea, and vomiting for its patients. Simultaneously, it has been a diagnostic dilemma for hospital emergency departments that attempt to decipher its diagnosis with various expensive and sometimes invasive tests that usually provide little insight to the problem.”
Dr. Russo has been seeking to understand the origins of CHS for years. In 2019, his company approached Len May, the CEO of EndoCanna Health, where Dr. Russo serves as a Scientific Advisory Board member, to find that they, too, cared about solving the mystery of CHS. Dr. Russo designed and oversaw a research study executed and analyzed by EndoCanna Health which led to the discovery of five genes that appear to occur in CHS patients at significantly higher rates than the general population. Where an individual has two or more of the five genes, it is an indication they are at much greater risk for CHS, which is triggered by chronic consumption of high THC cannabis and cannabis products.
Mr. May explains, “With the advent of this new technology, an inexpensive, simple mouth swab may provide insight to patients, their families, and physicians as to the source of the problem, and its impact.” Dr. Russo explains further the importance of this screening tool, “Our research has provided the understanding of CHS as a genetic susceptibility, and one that has implications for risks for other disorders including alcoholism, addiction to other substances, and risks for future development of heart disease and dementia, among others.”
We believe this technology will have important public health implications and offer significant savings in cost expenditures for unnecessary diagnostic tests, which patients surveyed have reported reaching $90,000-100,000. Highlighting the party’s collective intent to serve patients, Mr. May points out, “Through our HIPPA compliant process, we are able to provide the privacy patients desire with important data physicians need to aid in diagnosis and to educate patients about recovery.”
It is estimated approximately 50,000 people a year develop CHS. That figure is expected to increase significantly as cannabis legalization occurs across more jurisdictions globally. Some estimates for CHS prevalence have been as high as 2 million patients in the U.S., but no one knows.
Tests can be ordered by patients and physicians through the sales portal https://shop.endodna.com/products/chs-dna-susceptibility-test. Additional information about CHS is available at www.what-is-chs.com.
CReDO Science LLC is a biopharma holding company that exists to solve problems of the human/animal ECS including developing optimized formulations from the Cannabis plant for better living. Learn more at www.credo-science.com.
Endocanna Health is the industry leader in endocannabinoid system genomic testing and the manufacturer of genetically aligned formulations that create optimal cannabis experiences. Learn more at www.endodna.com.
###
